GHK: The Tissue Architect
GHK is a tripeptide present in human plasma at concentrations that decline with age — from approximately 200 ng/ml at age 20 to 80 ng/ml by age 60. Published research documents its modulation of over 4,000 human genes, including collagen synthesis pathways, antioxidant response elements, and DNA repair signaling. This review synthesizes the peer-reviewed evidence base.
Endogenous decline with age
Plasma GHK concentration declines from approximately 200 ng/ml at age 20 to roughly 80 ng/ml by age 60. This decline parallels the timeline of visible tissue changes — reduced wound healing capacity, declining collagen density, and impaired barrier function.
Gene expression modulation
Microarray analyses document GHK's modulation of over 4,000 human genes. Pathways affected include collagen and extracellular matrix synthesis, antioxidant response elements, DNA repair, and apoptosis regulation. The tripeptide functions as a broad-spectrum gene expression modulator rather than a single-pathway agonist.
Distinction from GHK-Cu
HelioMend formulas use the non-copper-chelated form of GHK. GHK-Cu — the copper-bound complex — is a distinct compound subject to FDA Category 2 compounding restrictions for injectable preparations. Topical non-copper GHK is not subject to those restrictions.
Transdermal feasibility
GHK's molecular weight of 340 Daltons places it well below the 500 Dalton threshold for passive transdermal penetration. PLGA nanoparticle formulations have demonstrated 94% entrapment efficiency and 90% release within 48 hours in published research.
Citations
- Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide. Int J Mol Sci. 2018;19(7):1987. [link]
- Abdulghani AA et al. Comparative collagen synthesis trial. Disease Management & Clinical Outcomes. 1999.
- Pickart L. The human tri-peptide GHK and tissue remodeling. J Biomater Sci Polym Ed. 2012;23(10):1387-99.